Skip to content

Clinical trials

Phase 1/2 trials in India

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Phase: Phase 1/2 Country / region: India Clear all

112 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20021
20042
20051
20061
20078
20089
20098
20108
20115
201210
20135
201418
20152
20165
20176
20181
20195
20202
20212
20222
20232
20243
20254
20261

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed51
Unknown status39
Terminated10
Recruiting6
Active, not recruiting2
Withdrawn2
Not yet recruiting2

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Chaitanya Hospital, Pune15
Kasiak Research Pvt. Ltd.8
Christian Medical College, Vellore, India3
International Stemcell Services Limited3
National Institute of Allergy and Infectious Diseases (NIAID)3
Piramal Enterprises Limited3
Tatyasaheb Kore Dental College3
Advanced Imaging Projects, LLC2
All India Institute of Medical Sciences2
Bharat Biotech International Limited2

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Breast Neoplasms5
Chronic Limb-Threatening Ischemia5
HIV Infections4
Osteoarthritis4
Chronic Periodontitis3
Diabetic Foot3
Neoplasms3
Spinal Cord Injuries3
Alopecia2
Arthritis, Rheumatoid2

Trials

Showing 76 to 100 of 112. Each trial links to its page on Pharma Observatory.

12 more trials match. See them on Pharma Observatory

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.